Clinical Trial: Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell

Brief Summary: This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.

Detailed Summary:

Inclusion criteria

  1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria
  2. age >20 yrs
  3. received rituximab+chemotherapy as first-line treatment
  4. with measurable or evaluable lesion
  5. with complete set of clinical and laboratory data for the analysis

Sponsor: Gachon University Gil Medical Center

Current Primary Outcome: Event-free survival [ Time Frame: one year ]

Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death)


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • complete response rate [ Time Frame: 1-year ]
    treatment response will be evaluated according to the Revised criteria for malignant lymphoma (Journal of Clinical Oncology 25:579-586)
  • overall survival [ Time Frame: 1-year ]
    Overall survival is defined as the time from treatment initiation until death as a result of any cause
  • Grade 4 hematologic toxicities [ Time Frame: one year ]
    toxicities will be graded according to Common Toxicity Criteria for Adverse Events (CTCAE) V.4.0. Hematologic toxicities planned to evaluated were; anemia (by hemoglobin), absolute neutrophil count, and platelet count


Original Secondary Outcome: Same as current

Information By: Gachon University Gil Medical Center

Dates:
Date Received: March 8, 2013
Date Started: February 2013
Date Completion:
Last Updated: February 22, 2017
Last Verified: February 2017